Limits...
Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer.

Horiguchi J, Takei H, Koibuchi Y, Iijima K, Ninomiya J, Uchida K, Ochiai R, Yoshida M, Yokoe T, Iino Y, Morishita Y - Br. J. Cancer (2002)

Bottom Line: When evaluated in patients treated with 5-fluorouracil or 5-fluorouracil derivatives, patients with dihydropyrimidine dehydrogenase-positive tumours had a significantly (P<0.05) poorer disease-free survival compared to those with dihydropyrimidine dehydrogenase-negative tumour.No conclusion can be drawn about the prognostic impact of dihydropyrimidine dehydrogenase status in patients who were not treated with 5-fluorouracil regimes due to the small number of such cases in this series.In conclusion, dihydropyrimidine dehydrogenase is a possible prognostic factor in patients with breast cancer treated with 5-fluorouracil or 5-fluorouracil derivatives.

View Article: PubMed Central - PubMed

Affiliation: Second Department of Surgery, Gunma University Faculty of Medicine, Showa-machi 3-39-15, Maebashi, Gunma 371-8511, Japan. junhorig@showa.gunma-u.ac.uk

Show MeSH

Related in: MedlinePlus

Immunohistochemical staining for DPD. (A) Grade 0 (no staining), (B) grade 2 (weak), (C) grade 3 (intermediate), (D) grade 3 (strong).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375185&req=5

fig1: Immunohistochemical staining for DPD. (A) Grade 0 (no staining), (B) grade 2 (weak), (C) grade 3 (intermediate), (D) grade 3 (strong).

Mentions: This is an antibody highly specific against rhDPD expressed in the baculovirus-expression system using human DPD cDNA. The expressed rhDPD protein has been found to retain the entire molecular form and to show a high 5-FU-degrading activity equivalent to that of the human liver DPD. Using this recombinant protein, polyclonal antibody was generated and investigated for its specificity, relationship to enzyme activity and the possibility of immunohistochemical measurement of tumoral DPD. The polyclonal antibody reacted with both human and rodent DPD. Tumour cells expressing high levels of DPD showed strongly positive staining, but those expressing low level or no DPD showed no staining (Okabe et al, 2000). The sections were rinsed with a buffer solution, and peroxidase labelled polymer was incubated for 30 min at room temperature. After the sections were washed with a buffer solution, the peroxidase reaction developed with diaminobenzidine tetrahydrochloride, and nuclei were counterstained with haematoxylin. DPD staining was noted in the cytoplasm of the cancer cells. DPD staining results were classified into four grades (0: no staining, 1: weak, 2: intermediate, and 3: strong) according to the intensity (Figure 1A, B, C and DFigure 1


Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer.

Horiguchi J, Takei H, Koibuchi Y, Iijima K, Ninomiya J, Uchida K, Ochiai R, Yoshida M, Yokoe T, Iino Y, Morishita Y - Br. J. Cancer (2002)

Immunohistochemical staining for DPD. (A) Grade 0 (no staining), (B) grade 2 (weak), (C) grade 3 (intermediate), (D) grade 3 (strong).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375185&req=5

fig1: Immunohistochemical staining for DPD. (A) Grade 0 (no staining), (B) grade 2 (weak), (C) grade 3 (intermediate), (D) grade 3 (strong).
Mentions: This is an antibody highly specific against rhDPD expressed in the baculovirus-expression system using human DPD cDNA. The expressed rhDPD protein has been found to retain the entire molecular form and to show a high 5-FU-degrading activity equivalent to that of the human liver DPD. Using this recombinant protein, polyclonal antibody was generated and investigated for its specificity, relationship to enzyme activity and the possibility of immunohistochemical measurement of tumoral DPD. The polyclonal antibody reacted with both human and rodent DPD. Tumour cells expressing high levels of DPD showed strongly positive staining, but those expressing low level or no DPD showed no staining (Okabe et al, 2000). The sections were rinsed with a buffer solution, and peroxidase labelled polymer was incubated for 30 min at room temperature. After the sections were washed with a buffer solution, the peroxidase reaction developed with diaminobenzidine tetrahydrochloride, and nuclei were counterstained with haematoxylin. DPD staining was noted in the cytoplasm of the cancer cells. DPD staining results were classified into four grades (0: no staining, 1: weak, 2: intermediate, and 3: strong) according to the intensity (Figure 1A, B, C and DFigure 1

Bottom Line: When evaluated in patients treated with 5-fluorouracil or 5-fluorouracil derivatives, patients with dihydropyrimidine dehydrogenase-positive tumours had a significantly (P<0.05) poorer disease-free survival compared to those with dihydropyrimidine dehydrogenase-negative tumour.No conclusion can be drawn about the prognostic impact of dihydropyrimidine dehydrogenase status in patients who were not treated with 5-fluorouracil regimes due to the small number of such cases in this series.In conclusion, dihydropyrimidine dehydrogenase is a possible prognostic factor in patients with breast cancer treated with 5-fluorouracil or 5-fluorouracil derivatives.

View Article: PubMed Central - PubMed

Affiliation: Second Department of Surgery, Gunma University Faculty of Medicine, Showa-machi 3-39-15, Maebashi, Gunma 371-8511, Japan. junhorig@showa.gunma-u.ac.uk

Show MeSH
Related in: MedlinePlus